نتائج البحث

1

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

المؤلفون: Yasutoshi Kuboki, Yuko Mori, Yoichi Naito, Takahiro Kogawa, Nobuaki Matsubara, Shigeyuki Toyoizumi, Takashi Nagasawa, Kenichi Harano, Masafumi Ikeda, Natsuki Hori

المصدر: Investigational New Drugs

مصطلحات موضوعية: Adult, 0301 basic medicine, medicine.medical_specialty, Maximum Tolerated Dose, Anemia, Talazoparib, Cmax, Antineoplastic Agents, Phase 1, Poly(ADP-ribose) Polymerase Inhibitors, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Asian People, Japan, Pharmacokinetics, Phase I Studies, Neoplasms, Internal medicine, medicine, Maculopapular rash, Clinical endpoint, Humans, Pharmacology (medical), Neoplasm Metastasis, Adverse effect, Stomatitis, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, Middle Aged, medicine.disease, PARP inhibitor, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Phthalazines, Safety, Neoplasm Grading, medicine.symptom, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ed123337d8369dfb1f4c651d0abc67Test
https://doi.org/10.1007/s10637-021-01120-7Test

2

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

المؤلفون: Lei Huo, Gaiane M. Rauch, Alyson Clayborn, Tanbin Rahman, Pamela McCarthy, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Stacy L. Moulder, Clinton Yam, W. Fraser Symmans, Jason B White, James Stec, Sausan Abouharb, Bora Lim, Jennifer K. Litton, Senthil Damodaran, Meghan Sri Karuturi, Ryan Sun

المصدر: Investigational New Drugs. 39:509-515

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6b9d56eaf08effcaff310abab6d9d7Test
https://doi.org/10.1007/s10637-020-00995-2Test

3

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

المصدر: Investigational new drugs, vol 39, iss 1
Invest New Drugs

مصطلحات موضوعية: 0301 basic medicine, Oncology, Organoplatinum Compounds, Metastatic pancreatic adenocarcinoma, Leucovorin, Phases of clinical research, Kaplan-Meier Estimate, Polyethylene Glycols, 0302 clinical medicine, FOLFOX, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), 6.2 Cellular and gene therapies, Cancer, education.field_of_study, Pharmacology and Pharmaceutical Sciences, Middle Aged, Progression-Free Survival, Interleukin-10, Tolerability, Pancreatic Ductal, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, IL-10, Fluorouracil, Pegilodecakin, Drug, Carcinoma, Pancreatic Ductal, medicine.drug, Adult, medicine.medical_specialty, Clinical Trials and Supportive Activities, Population, Phase 1, Article, Dose-Response Relationship, Pancreatic Cancer, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Pegylated IL-10, Adverse effect, education, Response Evaluation Criteria in Solid Tumors, Neoplasm Staging, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, Carcinoma, Evaluation of treatments and therapeutic interventions, digestive system diseases, Oxaliplatin, Pancreatic Neoplasms, Regimen, 030104 developmental biology, Tumor progression, Digestive Diseases, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69d0ddd9f3551a8ca0a4d0daab7d846Test
https://doi.org/10.1007/s10637-020-01000-6Test

4

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

المصدر: Invest New Drugs

مصطلحات موضوعية: Mesothelioma, Male, 0301 basic medicine, Oncogene Proteins, Fusion, Ligands, Gastroenterology, Hyperphosphatemia, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, FGF, Pharmacology (medical), Aged, 80 and over, Middle Aged, Treatment Outcome, Pemetrexed, Oncology, 030220 oncology & carcinogenesis, Female, Fibroblast Growth Factor 2, medicine.drug, Adult, medicine.medical_specialty, Combination therapy, Recombinant Fusion Proteins, Antineoplastic Agents, Phase 1, Article, 03 medical and health sciences, Pharmacokinetics, Internal medicine, medicine, Humans, Receptor, Fibroblast Growth Factor, Type 1, Adverse effect, Aged, Pharmacology, Cisplatin, business.industry, Mesothelioma, Malignant, Cancer, medicine.disease, 030104 developmental biology, Immunoglobulin G, Ligand trap, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f79fa27ba3514b5c0a71da97b74f5a9Test
https://doi.org/10.1007/s10637-019-00783-7Test

5

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

المؤلفون: Xuejing Wang, Katherine M Bell-McGuinn, Jimmy Hwang, Johanna C. Bendell, Hans Christian Reinhardt, Daphne L. Farrington, Celine Pitou, Helge Bischoff, Robert M. Campbell, Thomas Zander, Scott M. Hynes, Philip W. Iversen, Michael Thomas

المصدر: Investigational New Drugs. 38:1145-1155

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Pyridines, Population, Antineoplastic Agents, Models, Biological, p38 Mitogen-Activated Protein Kinases, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Lung cancer, Adverse effect, education, Protein Kinase Inhibitors, Aged, Pharmacology, education.field_of_study, business.industry, Imidazoles, Cancer, Common Terminology Criteria for Adverse Events, Middle Aged, medicine.disease, Treatment Outcome, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, Pyrazines, 030220 oncology & carcinogenesis, Checkpoint Kinase 1, Pyrazoles, Ralimetinib, Female, business, Febrile neutropenia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e75a04ddc23ef75c870beb94be16d9dTest
https://doi.org/10.1007/s10637-019-00873-6Test

6

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

المؤلفون: David Dai, Shuchi Sumant Pandya, Ingo K. Mellinghoff, Maeve A. Lowery, Erika Manyak, Patrick Y. Wen, Bin Fan, Lipika Goyal, Molly Prahl Judge, Sam Agresta, Tara Nimkar, Liewen Jiang, Guowen Liu, William D. Tap, Hua Yang, Camelia Gliser

المصدر: Investigational New Drugs

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb8d1211dda7c32ea032d7647d9a74aTest
http://europepmc.org/articles/PMC7066280Test

7

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

المؤلفون: Anthony W. Tolcher, Kyriakos P. Papadopoulos, Rashmi Chugh, David Smith, Robert Joseph Stagg, Ann M. Kapoun, Amita Patnaik, Min Wang, Lu Xu, Jakob Dupont

المصدر: Investigational New Drugs

مصطلحات موضوعية: 0301 basic medicine, Adult, Diarrhea, Male, medicine.medical_specialty, Abdominal pain, Tarextumab, Maximum Tolerated Dose, Nausea, Vomiting, Antineoplastic Agents, Phase 1, Gastroenterology, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Phase I Studies, Neoplasms, medicine, Humans, Pharmacology (medical), Receptor, Notch2, Adverse effect, Receptor, Notch3, Fatigue, Aged, Pharmacology, Aged, 80 and over, business.industry, Antibodies, Monoclonal, Middle Aged, Notch inhibition, Anorexia, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Pharmacodynamics, Toxicity, Every Three Weeks, Female, medicine.symptom, business, Transcriptome

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab597136745efa35e8542d8038e7b360Test
http://europepmc.org/articles/PMC6647865Test

8

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials

المؤلفون: Sanjay Goel, Audrey E. Kam, Ioannis Mantzaris, Santiago Aparo, Andreas Kaubisch, M. H. Ghalib, Gopichand Pendurti, Jennifer W. Chuy, Umang Shah, Imran Chaudhary, Lakshmi Rajdev

المصدر: Invest New Drugs

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Maximum Tolerated Dose, Colorectal cancer, Disease, Article, Survival outcome, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Tissue Distribution, Pharmacology (medical), Progression-free survival, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Pharmacology, Models, Statistical, Framingham Risk Score, business.industry, Patient Selection, Phase 1 trials, Phase i trials, Middle Aged, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Prognostic model, Female, Colorectal Neoplasms, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e7980ad2672d11c6f466b0df5b1adf3Test
https://doi.org/10.1007/s10637-018-0675-9Test

9

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy

المؤلفون: Takaaki Tokito, Takashi Kojima, Hidenobu Ishii, Norikazu Matsuo, Kazuhiko Yamada, Tomoaki Hoshino, Koichi Azuma

المصدر: Investigational new drugs. 39(4)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Combination therapy, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Disease, Gastroenterology, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Immune system, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Adverse effect, Lung cancer, Immune Checkpoint Inhibitors, Pneumonitis, Aged, Retrospective Studies, Pharmacology, Aged, 80 and over, Chemotherapy, business.industry, Incidence (epidemiology), Incidence, Middle Aged, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33e9c0562b5d14a59198e2debd0714Test
https://pubmed.ncbi.nlm.nih.gov/33483882Test

10

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors

المؤلفون: Shigehisa Kitano, Naoki Fukuda, Kenji Tamura, Makiko Ono, Kan Yonemori, Junichi Tomomatsu, Jun Sato, Noboru Yamamoto, Toshio Shimizu, Shunji Takahashi, Kazuki Sudo, Satoru Iwasa, Takafumi Koyama, Shunsuke Kondo

المصدر: Investigational New Drugs

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Maximum Tolerated Dose, Antineoplastic Agents, Ubiquitin-Activating Enzymes, Phase 1, Gastroenterology, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pharmacokinetics, Liver Function Tests, Internal medicine, Neoplasms, Phase I Studies, Solid tumors, medicine, Humans, Pharmacology (medical), Pyrroles, Dosing, Stage (cooking), Adverse effect, Aged, Pharmacology, medicine.diagnostic_test, biology, Dose-Response Relationship, Drug, business.industry, TAS4464, Middle Aged, Discontinuation, 030104 developmental biology, Pyrimidines, Treatment Outcome, Oncology, Enzyme inhibitor, 030220 oncology & carcinogenesis, NEDD8 activating enzyme E1 inhibitor, biology.protein, Female, Liver function, Chemical and Drug Induced Liver Injury, Safety, business, Liver function tests

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac6ac972d01ecaf4b81ee6784d289774Test
https://pubmed.ncbi.nlm.nih.gov/33560503Test

تنقيح النتائج